ASX
Every company in the roster listed on ASX.
Every company in the roster listed on ASX.
5 of 5 companies
| Company | Pipeline | Most advanced | Next readout | Market cap | Cash & inv. | Runway | R&D / yr |
|---|---|---|---|---|---|---|---|
Actinogen Medical (ASX: ACW)ACW · ASX | 1 asset: 1 Ph 3 | EmestedastatPhase 2/3 · Alzheimer's DiseasePartial signal | None on record | — | — | Ended Aug 2025Jun 2025 | ~$6.0M |
AdAlta1AD · ASX | 1 asset: 1 Ph 1 | AD-214Phase 1 · Chronic Kidney DiseaseWeak signal | None on record | — | $0.9MJun 2025 | Ended Jul 2025 | — |
Imugene LimitedIMU · ASX | 1 asset: 1 Ph 1 | Azercabtagene zapreleucelPhase 1 · Multiple Sclerosis | 1 Dec 2026Azercabtagene zapreleucel · Phase 1 | — | — | — | — |
Mayne PharmaMYX · ASX | 2 assets: 2 approved | Approved assets only | None on record | — | — | — | — |
Neuren PharmaceuticalsNEU · ASX | 1 asset: 1 approved | Approved assets only | None on record | — | — | — | — |
Next readout: the earliest estimated primary completion of a trial the company or a partner on the asset runs (ClinicalTrials.gov). Cash shows its balance-sheet month; runway shows a month only when it comes from an earlier report.